Edit

T1D Fund

http://www.t1dfund.org
Last activity: 22.05.2024
Probably Closed
Invests in categories: BioTechPlatformDevelopmentMedTechHealthTechDeliveryDrugTechnologyHardwareHuman
Portfolio
30
Persons
7
Mentions
18
Employees: 1-10
Investment Stage: Seed; Series A; Series B

Portfolio 30

DateNameWebsiteTotal RaisedLocation
10.03.2024vTv Therap...vtvtherapeutics.com-United Sta...
10.03.2024Sana Biote...sana.com$2.79BUnited Sta...
10.05.2023DiogenXdiogenx.com$35.2MFrance, Pr...
02.08.2022Egle Thera...egle-tx.com-France, Il...
13.08.2021GentiBiogentibio.com$177MUnited Sta...
21.07.2021Abata Ther...abatatx.com$95MUnited Sta...
16.07.2021Kriya Ther...kriyatherapeutics.com$370MUnited Sta...
05.09.2019Veralox Th...veraloxtx.com$5.4M-
-GluSense M...glusensemedical.com--
-Pandion Th...pandiontx.com$138MUnited Sta...
Show more

Persons 7

DateFirst NameLast NameTitleLinkedInLocation
-MattWilliamsDirector o...-
-ClayRowlandAssociatelinkedin.c...-
-NandanPadukone-linkedin.c...-
-SeanO'ConnorPrincipal-
-KatieElliasManaging D...linkedin.c...-
-YuryKukushkin-linkedin.c...-
-WilliamOrentAssociatelinkedin.c...-

Mentions in press and media 18

DateTitleDescription
28.02.2024vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund-
24.10.2023Former Novo Nordisk Executive, Dr. Todd Hobbs, joins Diasome Pharmaceuticals as Chief Medical OfficerDr. Todd Hobbs, Former North American Chief Medical Officer at Novo Nordisk, to Guide Diasome's HDV Platform Expansion The Fund is proud to work alongside the company’s management team – including Dr. Hobbs – as they advance their high impa...
11.05.2023Biotech startup DiogenX secures €27.5M to develop therapeutic solutions for Type 1 diabetesMarseille-based DiogenX, a preclinical-stage biotech company specialising in the development of pancreatic beta-cell modulators for the treatment of diabetes, announced on Wednesday, May 10, that it has raised €27.5M in a Series A round of ...
09.11.2020Protomer Gets Boost to Develop Glucose Responsive InsulinProtomer Technologies Inc., a Pasadena-based biopharmaceutical startup, closed a second round of funding to expand the tech platform it's using to develop insulin that adjusts according to a diabetes patient's blood sugar levels. The undisc...
09.11.2020Pasadena Biopharma Startup Protomer Gets an Investment BoostProtomer Technologies Inc., a Pasadena-based biopharmaceutical startup, closed a second round of funding to expand the tech platform it's using to develop insulin that adjusts according to a diabetes patient's blood sugar levels. The undisc...
05.09.2019Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led by JDRF T1D Fund and Sanofi VenturesFunding to Advance Development of Drug Candidates Targeting Heparin-Induced Thrombocytopenia and Type 1 Diabetes
05.09.2019Veralox Therapeutics Raises $5.4 Million in Seed Funding Co-Led by JDRF T1D Fund and Sanofi VenturesFREDERICK, Md.--(BUSINESS WIRE)--Veralox Therapeutics, a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, today announced it has raised a $5.4 million seed funding rou...
04.10.2018Precision medicine needs a business mindset in order to flourishPrecision medicine, also known as personalized medicine, has the potential to transform how we treat — or even cure — cancer and a host of other diseases such as cystic fibrosis, Parkinson’s, and Alzheimer’s. The precision approach to patie...
18.07.2018JDRF T1D Fund Appoints Ellias as Managing DirectorThe JDRF T1D Fund, a venture philanthropy fund focused on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic commercial investments, today announced that Katie Ellias has joined the fund...
18.07.2018JDRF T1D Fund Appoints Ellias as Managing DirectorThe JDRF T1D Fund, a venture philanthropy fund focused on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic commercial investments, today announced that Katie Ellias has joined the fund...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In